Clinical Evaluation of [68Ga]Ga-XT771 PET for Diagnosis in Patients With Glioblastoma and Clear Cell Renal Cell Carcinoma

This study is evaluating a new PET scan imaging agent called [68Ga]Ga-XT771 — a radiotracer injected before imaging to highlight certain tumor cells — to see how accurately it can detect and visualize glioblastoma (an aggressive brain tumor) and clear cell renal cell carcinoma (a common type of kidney cancer) in patients. **You may be eligible if...** - You are 18 or older - You have been diagnosed with glioblastoma (a type of brain cancer) or clear cell renal cell carcinoma (a type of kidney cancer) - You have signed an informed consent form to participate **You may NOT be eligible if...** - You have a known allergy to any component of the imaging agent or similar compounds - You have a medical condition considered incompatible with the study procedures - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.